QRxPharma wins US patent for opioid compounds
QRxPharma (ASX:QRX) has received a US patent covering the development of hybrid opioid compounds.
The patent encompasses a hybrid morphine-oxycodone molecule, where the two opioids are chemically linked. The patent expires in 2031.
QRxPharma is seeking US FDA approval for MoxDuo, a formulation consisting of morphine and oxycodone in the same tablet, and expects a decision on the immediate-release version shortly.
The company already holds a US patent covering the use of morphine and oxycodone in the same capsule, granting protection for both the immediate- and controlled-release versions through to 2023.
But the new patent covers chemically linking the two opioids to form a new composition of matter more potent than they would be if administered separately.
QRxPharma CEO Dr John Haloday said the new patent “protects next-generation dual-opioid combination products that are chemically unique”.
The company has licensed MoxDuo IR to Actavis in a deal worth up to US$150 million ($158.9 million).
QRxPharma shares were trading unchanged at $1.19 as of around 1 pm on Thursday.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
